Étiquette : cannabinoïde

Bibliographie : Cannabis et Cannabinoides en Psychiatrie, Docteur Christian Sueur, GRECC, janvier 2022

Bibliographie : Cannabis et Cannabinoides en Psychiatrie   Docteur Christian Sueur, GRECC, janvier 2022. (5e version, janvier 2022....)   1 - Généralités : 1 - 11 2 -Cannabinoïdes et anxiété : 12 3 - Cannabidiol anxiolytique : 13 - 15 4 - Cannabidiol antipsychotique : 16 - 21 5 - Cannabinoïdes et dépression : 22 - 28 6 - Cannabidiol antidépresseur : 28 7 - Cannabinoïdes et Sommeil : 29 - 30 8 - Cannabinoïdes et addiction / Substance Use Disorders : 31 - 33 9 - Cannabinoïdes et addiction au Cannabis : 34 - 43 10 - Cannabinoïdes et addictions (cocaine, opiacés, amphétamines, alcool, tabac) : 44 - 57 11 - Cannabinoides et syndrome de Gilles [...]

Lire la suite

Regulation of nausea and vomiting by cannabinoids, Linda A Parker et al., 2011

Regulation of nausea and vomiting by cannabinoids Linda A Parker, Erin M Rock and Cheryl L Limebeer British Journal of Pharmacology, 2011, 163, 1411-1422. Doi : 10.1111/j.1476-5381.2010.01176.x   Abstract Considerable evidence demonstrates that manipulation of the endocannabinoid system regulates nausea and vomiting in humans and other animals. The anti-emetic effect of cannabinoids has been shown across a wide variety of animals that are capable of vomiting in response to a toxic challenge. CB1 agonism suppresses vomiting, which is reversed by CB1 antagonism, and CB1 inverse agonism promotes vomiting. Recently, evidence from animal experiments suggests that cannabinoids may be especially useful in treating the more difficult to control [...]

Lire la suite

Therapeutic potential of cannabinoid medicines, Philip J. Robson, 2014

Therapeutic potential of cannabinoid medicines Philip J. Robson Drug and Testing Analysis, 2014 Doi : 10.1002/dta.1529   Cannabis was extensively used as amedicine throughout the developed world in the nineteenth century but went into decline early in the twentieth century ahead of its emergence as the most widely used illicit recreational drug later that century. Recent advances in cannabinoid pharmacology alongside the discovery of the endocannabinoid system (ECS) have re-ignited interest in cannabis-based medicines. The ECS has emerged as an important physiological system and plausible target for new medicines. Its receptors and endogenous ligands play a vital modulatory role in diverse functions including immune response, [...]

Lire la suite

Therapeutic potential of cannabinoids in schizophrenia, KUCEROVA J. et al., 2014

Therapeutic potential of cannabinoids in schizophrenia, KUCEROVA J., TABIOVA K., DRAGO F., MICALE V. Recent Patents on CNS Drug Discovery, 2014, 9, (1), 13-25. Doi : 10.2174/1574889809666140307115532   Abstract Increasing evidence suggests a close relationship between the endocannabinoid system and schizophrenia. The endocannabinoid system comprises of two G protein-coupled receptors (the cannabinoid receptors 1 and 2 [CB1 and CB2] for marijuana's psychoactive principle Δ(9)-tetrahydro-cannabinol), their endogenous small lipid ligands (namely anandamide [AEA] and 2-arachidonoyl-glycerol [2-AG], also known as endocannabinoids), and proteins for endocannabinoid biosynthesis and degradation. It has been suggested to be a pro-homeostatic and pleiotropic signalling system activated in a time- and tissue-specific manner during [...]

Lire la suite

Cannabinoids and Schizophrenia : Risks and Therapeutic Potential, Marc W. Manseau & Donald C. Goff, 2015

Cannabinoids and Schizophrenia : Risks and Therapeutic Potential Marc W. Manseau & Donald C. Goff Neurotherapeutics, 2015, 12, 816–824 DOI 10.1007/s13311-015-0382-6 # The American Society for Experimental NeuroTherapeutics, Inc. 2015   Abstract A convergence of evidence shows that use of Cannabis sativa is associated with increased risk of developing psychotic disorders, including schizophrenia, and earlier age at which psychotic symptoms first manifest. Cannabis exposure during adolescence is most strongly associated with the onset of psychosis amongst those who are particularly vulnerable, such as those who have been exposed to child abuse and those with family histories of schizophrenia. Schizophrenia that develops after cannabis use may have a [...]

Lire la suite

Plastic and Neuroprotective Mechanisms Involved in the Therapeutic Effects of Cannabidiol in Psychiatric Disorders, Alline C. Campos et al.,

Plastic and Neuroprotective Mechanisms Involved in the Therapeutic Effects of Cannabidiol in Psychiatric Disorders Alline C. Campos, Manoela V. Fogaça, Franciele F. Scarante, Sâmia R. L. Joca, Amanda J. Sales, Felipe V. Gomes, Andreza B. Sonego, Naielly S. Rodrigues, Ismael Galve-Roperh, and Francisco S. Guimarães Frontiers in Pharmacology, 2017. doi: 10.3389/fphar.2017.00269   Beneficial effects of cannabidiol (CBD) have been described for a wide range of psychiatric disorders, including anxiety, psychosis, and depression. The mechanisms responsible for these effects, however, are still poorly understood. Similar to clinical antidepressant or atypical antipsychotic drugs, recent findings clearly indicate that CBD, either acutely or repeatedly administered, induces plastic changes. [...]

Lire la suite

Cannabinoids, Neurogenesis and Antidepressant Drugs : Is there a Link ?, Manoela Viar Fogaça et al., 2013

Cannabinoids, Neurogenesis and Antidepressant Drugs : Is there a Link ? Manoela Viar Fogaça, Ismael Galve-Roperh, Francisco Silveira Guimarães and Alline Cristina Campos Current Neuropharmacology, 2013, 11, 263-275 Abstract Similar to clinically used antidepressants, cannabinoids can also regulate anxiety and depressive symptoms. Although the mechanisms of these effects are not completely understood, recent evidence suggests that changes in endocannabinoid system could be involved in some actions of antidepressants. Chronic antidepressant treatment modifies the expression of CB1 receptors and endocannabinoid (EC) content in brain regions related to mood and anxiety control. Moreover, both antidepressant and cannabinoids activate mitogen-activated protein (MAP) kinase and phosphoinositide 3- kinase(PI3 [...]

Lire la suite